# A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer

> **NCT07652515** · PHASE4 · NOT_YET_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 100 (estimated)

## Conditions studied

- Neoplasms, Endometrial

## Interventions

- **DRUG:** Dostarlimab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT07652515
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-17
- **Primary completion:** 2030-08-30
- **Final completion:** 2030-08-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07652515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07652515, "A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07652515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*